Michael Thomas Heffernan, Director at Trevi Therapeutics, Inc. (TRVI), sold 39,373 shares at $15.09 ($594K) on 2026-09-15, disclosed to the SEC on 2026-09-17.
Scheduled sale ($594k) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $15.09 | 18,321 | $276K | 46.5% |
| 2 | $15.09 | 20,952 | $316K | 53.2% |
| 3 | $15.88 | 100 | $2K | 0.3% |
| Total | $15.09 avg | 39,373 | $594K | 100% |
| Filing → |
| COLL | SELL | 2022-12-14 | $8.4M | — | Filing → |
| COLL | SELL | 2021-03-17 | $2.5M | — | Filing → |
| COLL | SELL | 2020-08-12 | $500K | — | Filing → |